Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- 4D Molecular Therapeutics, Inc. 4D-150 is advancing into Phase 3 development for4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that the first patients have been enrolled across multiple sites in the 4SIGHT Phase 3 clinical trial evaluating 4D-150 for the treatment of diabetic macular edema (DME). The Company also reported 2-year data from the SPECTRA clinical trial.
- Route 92 Medical Announces U.S. FDA Clearance for the FreeClimb® 46 Catheter with Tenzing® 4Route 92 Medical announces U.S. FDA clearance for the FreeClimb 46 Catheter with Tenzing 4.
- Keros Therapeutics, Inc.Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMDInitial data expected in the first half of 2027
- Curonix Announces Published PNS IMPACT Clinical Study Showing Freedom® Peripheral Nerve Stimulator (PNS) System is Associated with Reductions in Pain Scores, Opioid Use and Overall Patient BurdenCuronix Announces Published PNS IMPACT Clinical Study
- Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate CancerStudy advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer
- Tianjin Perennial Medical Partners with Three Tianjin Public Hospitals to Form Medical Delegation, Attends MHTE 2026 in Mongolia to Promote Specialty Collaboration and Cross-Border Diagnosis and Treatment ChannelsSeptember 25–27, MHTE 2026 was held in Ulaanbaatar. Perennial General Hospital Tianjin, together with Tianjin Hospital, Tianjin Chest Hospital, and Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, formed a medical...
- Global Genetically Modified Experimental Animal Models Market Forecast, 2026-2032 - CRISPR, Humanized Models and AI Drive 12.49% CAGR, Creating a USD 5.01 Billion Market by 2032Boost ROI by aligning models with clinical goals, standardizing validation and data, using auditable AI, improving reproducibility and welfare, and adopting organoid and computational alternatives
- Global Aptamer-Drug Conjugates Market Outlook, 2026-2032 - AI-Enabled Discovery and Precision Delivery Drive Growth Toward USD 2.14 Billion at a 15.79% CAGRImprove ROI via validated target selection, parallel optimization, early assays, regulatory planning, AI governance, and laboratory, clinical and manufacturing partnerships
- Global Clinical Safety & Pharmacovigilance Services Market Forecast, 2026-2032 - AI-Enabled Safety Operations and Regulatory Complexity Drive 12.26% CAGR, Propelling the Market to USD 6.14 Billion by 2032Boost ROI through risk-based resource allocation, controlled AI automation, standardized data, vendor KPIs, integrated teams and strong regulatory governance
- Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of DirectorsLift Therapeutics today announced the appointment of Eva Ehrnrooth as Executive Head of Clinical Development and Chau Khuong to its Board of Directors.
- Dr Agravat Same Day Dental Implants Clinic & Wellness Center Sets New StandardsDr Agravat Dental Clinic & Implant Wellness Center introduces nationwide clinical protocols for AI-assisted dental implant surgery in India.
- SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP FinesLONDON, September 28, 2026--British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance.